Delivery Order SPE2DR25D2100-SPE2DR26FA1LT
- Not listed
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a $2,971.95 firm fixed-price delivery order from the Defense Logistics Agency on January 15, 2026, for Repatha 140 mg/ml SureClick auto-injectors. The award is unset-aside and competitively awarded, with an ultimate completion date of January 16, 2026. This delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s comprehensive Indefinite Delivery Contract...
- AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc., was awarded a delivery order valued at $31,317.04 by the Defense Logistics Agency (DLA) on January 23, 2026, for the supply of Repatha 140 mg/mL SureClick auto-injector pharmaceutical product. The contract is firm fixed-price with no set-aside designation and is scheduled for completion by January 26, 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under...
- Amerisourcebergen Drug Corp (a subsidiary of Cencora, Inc.) was awarded a delivery order valued at $12,175.92 on January 12, 2026, by the Defense Logistics Agency for the supply of Repatha 140 mg/mL SureClick auto-injectors. This non-competitive, firm fixed-price delivery order is expected to be completed by January 13, 2026, with performance occurring at the contractor's facility in Conshohocken, Pennsylvania. The award represents a task order issued under Amerisourcebergen's larger...
- Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., was awarded a delivery order valued at $44,909.34 by the Defense Logistics Agency on January 28, 2026, for the supply of Repatha 140 mg/mL SureClick auto-injectors. The contract represents a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open competition. Performance will be executed from the prime contractor's location in Conshohocken, Pennsylvania, with an ultimate completion date...
- Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., was awarded a $6,497.25 delivery order by the Defense Logistics Agency on January 21, 2026, for the supply of Repatha 140 mg/ml SureClick auto-injectors. The contract is non-competitive and structured as a firm fixed-price delivery order with an ultimate completion date of January 22, 2026. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order is executed under Amerisourcebergen's...
- Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., was awarded a delivery order valued at $7,258.92 by the Defense Logistics Agency (DLA) on January 13, 2026, for the supply of Repatha 140 mg/ml SureClick auto-injectors. The contract is a firm fixed-price delivery order with no set-aside designation, reflecting a competitively awarded transaction. Performance will be completed at the awardee's location in Conshohocken, Pennsylvania, with an ultimate completion date of January 14,...
- Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., received a delivery order award from the Defense Logistics Agency (DLA) on January 22, 2026, for Repatha 140 mg/ml SureClick auto-injectors valued at $20,648.93. This firm fixed-price delivery order is scheduled for completion by January 23, 2026, and represents a non-competitive, non-set-aside award. The products will be delivered to the company's headquarters location in Conshohocken, Pennsylvania. Repatha is a prescription medication...
- Amerisourcebergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $17,760.26 on January 12, 2026, for the supply of Repatha 140 mg/mL SureClick auto-injectors. This competitive award was made by the Defense Logistics Agency, a subordinate agency of the Department of Defense responsible for supplying medical and pharmaceutical products to military healthcare systems. The contract utilizes firm fixed pricing and is...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $88,386.24 on January 21, 2026, for the supply of Repatha 140 mg/ml SureClick auto-injectors. This firm fixed-price, non-set-aside contract is funded by the Defense Logistics Agency (DLA) and will be completed by January 22, 2026, with performance taking place at the contractor's Conshohocken facility. The award represents a task order under...
- AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc., was awarded a delivery order valued at $10,196.54 by the Defense Logistics Agency on January 6, 2026, for the supply of Repatha 140 mg/ml SureClick auto-injectors. This is a firm fixed-price, non-set-aside contract with a completion date of January 7, 2026, with performance occurring at AmerisourceBergen's Conshohocken, Pennsylvania location. The delivery order is issued under the company's larger Indefinite Delivery Contract with DLA...
- SPE2DR25D2100Indefinite Delivery Contract
- SPE2DR25D2100-SPE2DR26FA1LTDelivery Order
Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., was awarded a firm fixed-price delivery order valued at $33,760.01 by the Defense Logistics Agency on January 27, 2026, for the supply of Repatha 140 mg/mL SureClick auto-injector medication. The delivery order, which carries an ultimate completion date of January 28, 2026, represents a non-competitive award issued without set-aside designation. Performance will be executed from the awardee's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under Amerisourcebergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a comprehensive single-award vehicle valued at $999,999,999.00 through December 2026 that enables the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs globally. The Defense Logistics Agency's Medical Supply Chain relies on Amerisourcebergen as a critical vendor for pharmaceutical procurement supporting military treatment facilities and federal health systems. Repatha, a PCSK9 inhibitor indicated for cardiovascular disease management, represents the type of specialized pharmaceutical commodity delivered through the company's existing IDC framework. Amerisourcebergen's federal contracting portfolio demonstrates substantial capability in fulfilling government pharmaceutical needs across multiple therapeutic domains through competitive procurement mechanisms, positioning the company as a key supplier for military and veteran healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $33.8k | 1/26/26 |